高强度聚焦超声热疗治疗31例胰腺癌的临床分析  

High intensity focused ultrasound in patients with pancreatic carcinoma

作　　者：李亚岭[1] 罗建平[1] 李秋野[2] 李可夫[2] 

机构地区：[1]黄河中心医院消化内科,河南郑州450003 [2]黄河中心医院高强度超声聚焦刀中心,河南郑州450003

出　　处：《胃肠病学和肝病学杂志》2008年第9期711-713,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的探讨高强聚焦超声(HIFU)热疗对胰腺癌患者的疗效、安全性及对几种肿瘤标志物的影响。方法31例胰腺癌患者平均每例患者行7.2次HIFU治疗,对其进行疗效评价,观察患者的临床受益反应(CBR)、肿瘤客观评价、化学免疫分析法检测CA19-9、CA242和CEA浓度。结果31例胰腺癌患者中共20例临床受益,CBR率达64.51%。治疗前-后CA19-9、CA242、CEA浓度差异具有统计学意义。在治疗过程中无明显副作用。结论高强聚焦超声热疗能控制肿瘤进展、改善生活质量、对肿瘤标志CA19-9、CA242、CEA有有明显下调作用,无明显不良反应。Objective To investigate the therapeutic effect, safety and the effect of several tumor markers of high intensity focused ultrasound （HIFU） in treating pancreatic carcinoma. Methods The 31 patients suffering from pancreatic carcinoma received 7.2 times in average HIFU treatment, and we observed therapeutic effects including of clinical benefit response, tumorous objective evaluation, the concentration of several tumor markers to utilize chemo-immunity analytical method detecting of carbohydrate antigen 19-9 （CA19-9）, CA 242, carcino-embryonic antigen（CEA）. Re- sults There were 20 clinical benefit response among 31 pancreatic carcinoma patients received high intensity focused ultrasound （HIFU）. The clinical benefit response rate was 64.51%. The concentration of CA19-9, CA242, CEA, the variability was significant before and after the treatment. The treatment course was well in the observation group. The complicated symptoms did not perform after the treatment. Conclusion The HIFU in treating pancreatic carcinoma can control the progress of tumor, improve the quality of life, and prolong overall survival. It also can reduce CA19-9, CA242 and CEA levels. Furthermore, no significant adverse reaction oecurres in the treatment.

关 键 词：高强度聚焦超声 胰腺癌 

分 类 号：R735.9[医药卫生—肿瘤]